De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND Bronchiolitis obliterans syndrome (BOS) is the major cause of late graft failure after lung transplantation. The objective was to determine whether de novo donor human leukocyte antigen (HLA)-specific antibodies (DSA) are associated with the development of BOS or patient survival. Data were analyzed from 188 lung transplant recipients with a follow-up period up to 8 years. METHODS HLA antibody monitoring was performed at 3-month intervals post-transplant at routine outpatient clinic attendances and during the investigation of any acute deterioration. HLA antibody data were available for 148 patients; 66 (45%) had produced HLA antibodies after transplant, of which 38 (26%) were DSA and 28 (19%) non-donor-specific HLA antibodies. RESULTS De novo DSA was associated with development of BOS Stage 1 (BOS1; hazard ratio [HR] = 2.302, p = 0.0015), BOS2 (HR = 3.627, p < 0.0001) and BOS3 (HR = 5.736, p < 0.0001). De novo persistent DSA correlated strongly with shorter time to onset of BOS3 (HR = 6.506, p = 0.0001). There was a significant reduction in patient survival associated with de novo DSA (HR = 1.886, p = 0.047). In multivariable analyses, de novo DSA was an independent predictor for development of all stages of BOS as well as an independent predictor of poor patient survival. CONCLUSIONS De novo DSA is a major risk factor for progression to BOS and shorter patient survival. Treatments to remove antibodies or limit antibody-mediated damage could be considered when DSA are first detected. However, a randomized, controlled trial of treatment options would enable a clearer understanding of the benefits, if any, of antibody-removal therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Levine, D. J., Glanville, A. R., Aboyoun, C., Belperio, J., Benden, C., Berry, G. J., Hachem, R., Hayes, D., Neil, D., Reinsmoen, N. L., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.1223 · Cited by 488
Newton, C. A., Kozlitina, J., Lines, J. R., Kaza, V., Torres, F., & Garcia, C. K. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.02.005 · Cited by 132
Courtwright, A. M., El-Chemaly, S., Dellaripa, P. F., & Goldberg, H. J. (2017) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.12.013 · Cited by 73
The impact of pre-transplant allosensitization on outcomes after lung transplantation
Bosanquet, J. P., Witt, C. A., Bemiss, B. C., Byers, D. E., Yusen, R. D., Patterson, A. G., Kreisel, D., Mohanakumar, T., Trulock, E. P., & Hachem, R. R. (2015) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2015.06.003 · Cited by 45
Clinical outcomes of lung transplantation in the presence of donor-specific antibodies
Courtwright, A. M., Cao, S., Wood, I., Mallidi, H. R., Kawasawa, J., Moniodis, A., Ng, J., El-Chemaly, S., & Goldberg, H. J. (2019) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201812-869oc · Cited by 39
Metadata
- Authors
- Safavi, S., Robinson, D. R., Soresi, S., Carby, M., & Smith, J. D.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 33
- Issue
- 12
- Pages
- 1273-1281
- ISSN
- 1053-2498 (ISSN-L)
- OpenAlex
- W2123494912
- Cited by
- 129
- References
- 0
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. https://app.cochat.ai/papers/10.1016/j.healun.2014.07.012
- The paper
- Safavi, S., Robinson, D. R., Soresi, S., Carby, M., & Smith, J. D. (2014). De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2014.07.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.